Back to search

Article

PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine

2023-11-16

Abstract excerpt

<h4>Purpose</h4> The transmembrane protein CD37 is expressed almost exclusively in lymphoid tissues, with the highest abundance in mature B cells. CD37-directed antibody- and, more recently, cellular-based approaches have shown preclinical and promising early clinical activity. Naratuximab emtansine (Debio 1562, IMGN529) is an antibodydrug conjugate (ADC) that incorporates an anti-CD37 monoclonal antibody conjuga...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7d1cd333-7c74-5826-9e19-71de9dad2f80
DOI
10.1101/2023.11.14.566994
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansineDOI 10.1101/2023.11.14.566994
Comprehensive Analysis of <sup>177</sup> Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination SchemesSemantic proximity
GPR183 mediates the capacity of the novel CD47-CD19 bispecific antibody TG-1801 to heighten ublituximab-umbralisib (U2) anti-lymphoma activitySemantic proximity
Comprehensive Analysis of 177Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination SchemesSemantic proximity
Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)Semantic proximity
A Novel Bispecific Antibody Targeting Frizzled7 and PD-L1 Reverses Immunotherapy Resistance in Non-Small Cell Lung Cancer by Reprogramming the Tumor MicroenvironmentSemantic proximity
Efficacy of RMC-6236 (Daraxonrasib) and novel combination strategies targeting resistance in RAS pathway-driven neuroblastomaSemantic proximity
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasmsSemantic proximity
Current Knowledge and Perspectives of Immunotherapies for NeuroblastomaSemantic proximity
Inhibition of CDK4/6 Overcomes Primary Resistance to PD-1 Blockade in Malignant MesotheliomaSemantic proximity
Leveraging Synergy: The Therapeutic Potential of SN-38 and Immunotherapy in Breast and Prostate Cancer TreatmentSemantic proximity
Novel immunotherapeutics against LGR5 to target multiple cancer typesSemantic proximity
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.Semantic proximity
Select a neighboring publication to make it the new centre.